These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 15878587)

  • 1. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
    Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
    Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
    Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
    Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.
    Zesiewicz TA; Wecker L; Sullivan KL; Merlin LR; Hauser RA
    Clin Neuropharmacol; 2006; 29(3):106-11. PubMed ID: 16772808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
    Anamnart C; Kitjarak R
    J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
    Postuma RB; Espay AJ; Zadikoff C; Suchowersky O; Martin WR; Lafontaine AL; Ranawaya R; Camicioli R; Lang AE
    Neurology; 2006 Jun; 66(12):1941-3. PubMed ID: 16801668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
    Triantafyllou NI; Kararizou E; Angelopoulos E; Tsounis S; Boufidou F; Evangelopoulos ME; Nikolaou C; Vassilopoulos D
    Eur Neurol; 2007; 58(2):96-9. PubMed ID: 17565222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
    Kocer B; Guven H; Comoglu SS
    Biomed Res Int; 2016; 2016():7563705. PubMed ID: 27493964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homocysteine in restless legs syndrome.
    Bachmann CG; Guth N; Helmschmied K; Armstrong VW; Paulus W; Happe S
    Sleep Med; 2008 May; 9(4):388-92. PubMed ID: 17900981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
    Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of entacapone on homocysteine levels in Parkinson disease.
    Ostrem JL; Kang GA; Subramanian I; Guarnieri M; Hubble J; Rabinowicz AL; Bronstein J
    Neurology; 2005 Apr; 64(8):1482. PubMed ID: 15851757
    [No Abstract]   [Full Text] [Related]  

  • 13. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
    Kulisevsky J
    Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
    Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
    Parkinsonism Relat Disord; 2009 Jul; 15(6):477-8. PubMed ID: 19028438
    [No Abstract]   [Full Text] [Related]  

  • 18. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
    O'Suilleabhain PE; Bottiglieri T; Dewey RB; Sharma S; Diaz-Arrastia R
    Mov Disord; 2004 Dec; 19(12):1403-8. PubMed ID: 15390053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.